TenX Keane Acquisition Unit
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch TENKU and buy or sell other stocks, ETFs, and their options commission-free!About TENKU
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
CEOLeonard L. Mazur, MBA
CEOLeonard L. Mazur, MBA
Employees—
Employees—
HeadquartersCranford, New Jersey
HeadquartersCranford, New Jersey
Founded
Founded
Employees—
Employees—
TENKU Key Statistics
Market cap3.15B
Market cap3.15B
Price-Earnings ratio-231.09
Price-Earnings ratio-231.09
Dividend yield—
Dividend yield—
Average volume—
Average volume—
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$45.84
52 Week high$45.84
52 Week low$11.32
52 Week low$11.32
Stock Snapshot
The current TenX Keane Acquisition Unit(TENKU) stock price is $44.00, with a market capitalization of 3.15B. The stock trades at a price-to-earnings (P/E) ratio of -231.09.
On 2025-12-09, TenX Keane Acquisition Unit(TENKU) stock opened at —, reached a high of —, and a low of —.
The TenX Keane Acquisition Unit(TENKU)'s current trading volume is 0.
During the past year, TenX Keane Acquisition Unit(TENKU) stock moved between $11.32 at its lowest and $45.84 at its peak.
During the past year, TenX Keane Acquisition Unit(TENKU) stock moved between $11.32 at its lowest and $45.84 at its peak.